Boardroom Alpha
Start trial
10-Q primary document
LGVN · Quarterly Report (Form 10-Q) · Filed August 12, 2026

Longeveron Inc — 10-Q exhibit

lgvn-ex10_22.htm
Longeveron Inc on Boardroom Alpha
EX-10.22

Exhibit 10.22.1

LONGEVERON INC.

AMENDMENT NO. 1 TO AT THE MARKET OFFERING AGREEMENT

June 16, 2026

H.C. Wainwright & Co., LLC

430 Park Avenue

New York, NY 10022 Ladies and Gentlemen:

Reference is made to the At the Market Offering Agreement, dated September 19, 2025 (the “Sales Agreement”), by and between Longeveron Inc., a Delaware corporation (the “Company”), and H.C. Wainwright & Co., LLC (the “Manager”). Capitalized terms used herein but not otherwise defined are used herein as defined in the Sales Agreement.

The Company and the Manager (collectively, the “Parties”) wish to amend the Agreement, to be effective as of the date hereof, pursuant to Section 14 of the Sales Agreement, on the terms and conditions set forth in this letter (this “Amendment”). Therefore, for and in consideration of the mutual covenants and agreements herein contained, and contained in the Sales Agreement, the Company, on the one hand, and the Manager, on the other hand, the Parties therefore hereby agree as follows:

1.
The final sentence of Section 3(jj) of the Agreement is hereby amended and restated in its entirety to read as follows:

“Except as set forth in the SEC Reports, the Company has not been informed by the FDA that the FDA will prohibit the marketing, sale, license or use in the United States of any product proposed to be developed, produced or marketed by the Company. Except as set forth in the SEC Reports, the FDA has not expressed any concern in writing as to approving or clearing for marketing any product being developed or proposed to be developed by the Company, except as would not, individually or in the aggregate, reasonably be expected to result in a Material Adverse Effect.”

2.
Governing Law. THIS AMENDMENT SHALL BE SUBJECT TO THE PROVISIONS REGARDING APPLICABLE LAW AND WAIVER OF JURY TRIAL SET FORTH IN SECTIONS 15 AND 16 OF THE SALES AGREEMENT, AND SUCH PROVISIONS ARE INCORPORATED HEREIN BY THIS REFERENCE, MUTATIS MUTANDIS.
3.
Counterparts. This Amendment may be signed in one or more counterparts, each of which shall constitute an original and all of which together shall constitute one and the same agreement, which may be delivered by facsimile or in .pdf file via e-mail.
4.
Agreement Remains in Effect. Except as provided herein, all provisions, terms and conditions of the Sales Agreement shall remain in full force and effect. As amended hereby, the Sales Agreement is ratified and confirmed in all respects. On and after the date of this Amendment, each reference in the Sales Agreement to the “Agreement”, “hereinafter”, “herein”, “hereinafter”, “hereunder”, “hereof”, or words of like import shall mean and be a reference to the Sales Agreement as amended by this Amendment.

(Signature page follows.)

 

 

 


Exhibit 10.22.1

 

If the foregoing is in accordance with your understanding of our agreement, please sign and return to the Company a counterpart hereof; whereupon this instrument, along with all counterparts, will become a binding agreement by the Company and the Manager in accordance with its terms.

 

Very trulyyours,

LONGEVERON INC.

By:

Name: Stephen H. Willard

Title: Chief Executive Officer

 

The foregoing Amendment No. 1 to the Sales Agreement is hereby confirmed and accepted as of the datefirst written above.

H.C. WAINWRIGHT & CO., LLC

By: /s/ Merav Gershtenman

Name: Merav Gershtenman

Title: Chief Legal Officer

 

 

Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer